Psychedelics
GH Research Progresses Deeper Into Toad Venom Research
The company expects its current cash to fund it into 2026.
The post GH Research Progresses Deeper Into Toad Venom Research appeared first on Green Market…
Dublin-based clinical-stage biopharmaceutical firm GH Research PLC (Nasdaq: GHRS) released its second quarter financial results ending June 30, alongside a series of business updates as it continues to trial its trippy toad drug.
The company reported a cash position of $238.1 million, down from $251.7 million at the end of 2022. Despite the decline, GH Research said it expects these funds to sustain operating and capital expenses into 2026.
R&D expenses for the quarter reached $7.2 million, marking a rise from the $4.2 million in the second quarter of 2022. The surge is primarily linked to rising technical development and clinical trials. Meanwhile, G&A expenses edged up to $2.7 million from $2.5 million a year earlier.
The quarter ended with a net loss of $7.7 million, in stark contrast to the net profit of $300,000 in the second quarter of 2022, largely due to a one-time foreign exchange gain last year.
GH Research’s GH001, an inhalable mebufotenin product, is currently under a Phase 2b trial for treatment-resistant depression in Europe. The company anticipates initiating a Phase 1 trial for GH001 in the U.S. in the fourth quarter of 2023. Trials for its use in postpartum depression are set to end this year, but a study on bipolar II disorder is now predicted to conclude in early 2024.
Mebufotenin is a potent psychedelic that can be found in certain plant species and from the glands of a Colorado River toad. Former heavyweight boxing champion Mike Tyson famously uses the drug, the DMT analog of the tryptamine class, to help treat his PTSD and anxiety-depression.
GH002, another product, is undergoing a trial in healthy volunteers, expected to wrap up in the fourth quarter of 2023.
Additionally, GH Research announced an expansion of its executive team, with the appointment of Velichka (Villy) Valcheva as vice president of clinical research and medical affairs.
The post GH Research Progresses Deeper Into Toad Venom Research appeared first on Green Market Report.
dmt psychedelic analog depression anxiety ptsd nasdaq capital research
-
Psilocybin1 week agoCalifornia advances bill for psychedelics centers
-
Psilocybin5 days agoPassover Perspectives: Psychedelics, Moses, and the Burning Bush
-
Psychedelics1 week agoPsychedelics Can Offer More Than Therapy On Its Own
-
Psychedelics4 days agoAlgernon NeuroScience and the Centre for Human Drug Research to Present DMT Phase 1 Stroke Clinical Data at the Interdisciplinary Conference on Psychedelic Research June 6 – 8th, 2024
-
Psychedelics5 days agoRevive Therapeutics Announces Type C Meeting Request Granted by FDA for Clinical Study of Bucillamine to Treat Long COVID
-
Psychedelics5 days agoSilo Pharma Announces Positive Results for Intranasal PTSD Treatment
-
Psychedelics5 days ago
Silo Pharma Announces Positive Results for Intranasal PTSD Treatment
-
Psilocybin5 days agoPsilocybin and Meditation: Unlocking the Potential for Enhancing Insightfulness